pCODR
Prostate Cancer Canada (PCC) is a proud patient group member of the pan-Canadian Oncology Drug Review (pCODR). pCODR was established by Canada's provincial and territorial Ministries of Health (with the exception of Quebec) to assess cancer drug therapies and make recommendations to guide drug-funding decisions. PCC participates in this process by collecting feedback from patients and caregivers and submitting this feedback to pCODR.
To learn more about pCODR please visit their
website.
Current Drugs Under Review
No drugs are being reviewed at this time.
If you have any questions, please contact
drugcoverage@prostatecancer.ca